Osteoporosi e malattie metaboliche dell’osso (paragrafi da 1-11)
Diabete e dislipidemie (paragrafi da 12-22)
HIV e AIDS (paragrafi da 23-31)
Dopamina e sistema endocrino (paragrafi da 32-46)
Vasopressina, sete e disautonomia (paragrafi da42-52)
Obesità (paragrafi da12-14 e 18, da 20-22 e 33, da 53-55)
Sistema nervoso simpatico e recettri adrenergici (in vitro e in vivo) (paragrafi 39, 40, 50, da 56-72)
Prostaglandine e infiammazione (paragrafi 6, 12, 28, 31, 53, 54, 68, da 73-80)
Angiotensin converting enzyme and BNP (paragrafi 72, 81-86)

1.         Barbieri C, Baruto C, Sala M, Bigatti G, Parodi M, Bellini P, Bevilacqua M. Lack of effect of deflazacort, a novel glucocorticoid, on basal and TRH-stimulated prolactin and thyrotropin levels in healthy subjects. Eur J Clin Pharmacol 1985; 29:123-5.

2.         Weber G, De Angelis M, Cazzuffi MA, Frisone F, Bevilacqua M, Gaboardi F, Chiumello G. Hypocalciuric effect of chlorthalidone in two hypoparathyroid children. Helv Paediatr Acta 1986; 41:465-7.

3.         Monti M, Scazzoso A, Bevilacqua M, Santi I, D'Aprile E, Saligari A, Norbiato G, Cunietti E. Plasma monomeric calcitonin as a marker of disease activity in multiple myeloma patients with osteolysis. Int J Biol Markers 1992; 7:87-92.

4.         Bettica P, Bevilacqua M, Vago T, Norbiato G. High prevalence of hypovitaminosis D among free-living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening. Osteoporos Int 1999; 9:226-9.

5.         Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000; 247:63-70.

6.         Varenna M, Zucchi F, Ghiringhelli D, Binelli L, Bevilacqua M, Bettica P, Sinigaglia L. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol 2000; 27:1477-83.

7.         Adami S, Bevilacqua M, Broggini M, Filipponi P, Ortolani S, Palummeri E, Ulivieri F, Nannipieri F, Braga V. Short-term intravenous therapy with Neridronate in Paget's disease. Clin Exp Rheumatol 2002; 20:55-8.

8.         Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S. Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 2003; 14:577-82.

9.         Bevilacqua M, Dominguez, L.J., Righini, V., Valdes, V., Toscano, R., Sangaletti, O., Vago, T., Baldi, G., Barrella, M., Bianchi-Porro, G:. Increased gastrin and calcitonin secretion after oral calcium or peptones administration in patients with hypercalciuria: a clue to an alteration in calcium sensing receptor activity. Journal of Clinical Endocrinology and Metabolism 2005; in press.

10.       Marcocci C, Bevilacqua M. Fluoride and anabolic steroids in the treatment of glucocorticoid-induced osteoporosis. Front Horm Res 2002; 30:165-73.

11.       Bettica P, Bevilacqua M, Vago T, Masino M, Cucinotta E, Norbiato G. Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared. J Clin Endocrinol Metab 1997; 82:3034-9.

12.       Micossi P, Pontiroli AE, Baron SH, Tamayo RC, Lengel F, Bevilacqua M, Raggi U, Norbiato G, Foa PP. Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects. Diabetes 1978; 27:1196-1204.

13.       Rovati V, Brigante G, Bevilacqua M, Milanesi A. Pancreatoduodenectomy with neoprene occlusion of main pancreatic duct. Lancet 1984; 1:1241-2.

14.       Raggi U, Palumbo P, Moro B, Bevilacqua M, Norbiato G. Indapamide in the treatment of hypertension in non-insulin-dependent diabetes. Hypertension 1985; 7:II157-60.

15.       Caccia MR, Dezuanni E, Salvaggio A, Osio M, Bevilacqua M, Norbiato G, Mangoni A. Sympathetic skin response versus maximum motor and sensory conduction velocity to detect subclinical neuropathy in non-insulin-dependent diabetics. Acta Neurol Belg 1991; 91:213-22.

16.       Caccia MR, Osio M, Dezuanni E, Bevilacqua M, Bertora PL, Salvaggio A, Mangoni A, Norbiato G. Nerve conduction velocity distribution in normal subjects and in diabetic patients without clinical signs of neuropathy. II. Sensory nerve. Electromyogr Clin Neurophysiol 1992; 32:411-6.

17.       Caccia MR, Salvaggio A, Dezuanni E, Osio M, Bevilacqua M, Norbiato G, Mangoni A. An electrophysiological method to assess the distribution of the sensory propagation velocity of the digital nerve in normal and diabetic subjects. Electroencephalogr Clin Neurophysiol 1993; 89:88-94.

18.       Bevilacqua M, Bettica P, Milani M, Vago T, Rogolino A, Righini V, Santoli E, Norbiato G. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997; 79:84-7.

19.       Bertora P, Valla P, Dezuanni E, Osio M, Mantica D, Bevilacqua M, Norbiato G, Caccia MR, Mangoni A. Prevalence of subclinical neuropathy in diabetic patients: assessment by study of conduction velocity distribution within motor and sensory nerve fibres. J Neurol 1998; 245:81-6.

20.       Bevilacqua M GB, Righini V, Barrella M, Toscano R, Chebat E. Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded end-point (PROBE) trial. Current therapeutic Research 2004; 65:330-344.

21.       Foschi D, Corsi F, Pisoni L, Vago T, Bevilacqua M, Trabucchi A, Asti E, Trabucchi E. Plasma leptin levels after vertical banded gastroplasty for morbid obesity: effects of an acidified meal. Obes Surg 2003; 13:874-8.

22.       Foschi D, Corsi F, Pisoni L, Vago T, Bevilacqua M, Asti E, Righi I, Trabucchi E. Plasma cholecystokinin levels after vertical banded gastroplasty: effects of an acidified meal. Obes Surg 2004; 14:644-7.

23.       Norbiato G, Bevilacqua M, Vago T, Baldi G, Chebat E, Bertora P, Moroni M, Galli M, Oldenburg N. Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:608-13.

24.       Bevilacqua M. Hyponatraemia in AIDS. Baillieres Clin Endocrinol Metab 1994; 8:837-48.

25.       Clerici M, Bevilacqua M, Vago T, Villa ML, Shearer GM, Norbiato G. An immunoendocrinological hypothesis of HIV infection. Lancet 1994; 343:1552-3.

26.       Norbiato G, Bevilacqua M, Vago T, Clerici M. Glucocorticoids and interferon-alpha in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1996; 81:2601-6.

27.       Norbiato G, Bevilacqua M, Vago T, Taddei A, Clerici. Glucocorticoids and the immune function in the human immunodeficiency virus infection: a study in hypercortisolemic and cortisol-resistant patients. J Clin Endocrinol Metab 1997; 82:3260-3.

28.       Norbiato G, Bevilacqua M, Vago T, Clerici M. Glucocorticoids and Th-1, Th-2 type cytokines in rheumatoid arthritis, osteoarthritis, asthma, atopic dermatitis and AIDS. Clin Exp Rheumatol 1997; 15:315-23.

29.       Norbiato G, Bevilacqua M, Vago T. Glucocorticoids and the immune system in AIDS. Psychoneuroendocrinology 1997; 22 Suppl 1:S19-25.

30.       Norbiato G, Bevilacqua M, Vago T, Clerici M. Glucocorticoid resistance and the immune function in the immunodeficiency syndrome. Ann N Y Acad Sci 1998; 840:835-47.

31.       Reinke P, Bevilacqua M, Tryon V, Cheronis J, Volk HD. Immune monitoring of glucocorticoid therapy. Ernst Schering Res Found Workshop 2002:25-37.

32.       Norbiato G, Bevilacqua M, Raggi U, Micossi P, Moroni C. Metoclopramide increases plasma aldosterone concentration in man. J Clin Endocrinol Metab 1977; 45:1313-6.

33.       Norbiato G, Bevilacqua M, Raggi U, Micossi P. Dopaminergic activity in idiopathic oedema. Lancet 1977; 2:1088.

34.       Petrillo M, Prada A, Porro GB, Bevilacqua M, Raggi V, Norbiato G. Plasma-prolactin and cimetidine. Lancet 1977; 2:761.

35.       Norbiato G, Bevilacqua M, Raggi U, Micossi P, Nitti F, Lanfredini M, Barbieri S. Effect of metoclopramide, a dopaminergic inhibitor, on renin and aldosterone in idiopathic edema: possible therapeutic approach with levodopa and carbidopa. J Clin Endocrinol Metab 1979; 48:37-42.

36.       Bevilacqua M, Norbiato G, Raggi U, Micossi P, Baggio E, Prandelli M. Dopaminergic control of serum potassium. Metabolism 1980; 29:306-10.

37.       Norbiato G, Bevilacqua M, Vago T. Extrarenal potassium disposal. N Engl J Med 1980; 303:52.

38.       Bozzi G, Terranova P, Paolino C, Cialfi A, Gandini R, Bevilacqua M. [Effects of acute administration of metoclopramide on atrial and AV conduction in man]. Boll Soc Ital Cardiol 1981; 26:1853-5.

39.       Bevilacqua M, Vago T, Scorza D, Norbiato G. Characterization of dopamine receptors by 3H-ADTN binding in calf adrenal zona glomerulosa. Biochem Biophys Res Commun 1982; 108:1661-9.

40.       Bevilacqua M, Vago T, Raggi U, Scorza D, Proverbio M, Malacco E, Norbiato G. In vitro steroidogenic properties of FK 33 824, a stable analog of methionine-enkephalin. Opiate-dopamine interaction in the control of aldosterone production. J Endocrinol Invest 1982; 5:277-80.

41.       Bevilacqua M, Scorza D, Meroni R, Vago T, Dagani R, Malacco E, Norbiato G. Evidence for a role of a serum factor stimulated by metoclopramide in regulating aldosterone secretion. Biochem Biophys Res Commun 1984; 119:95-100.

42.       Norbiato G, Bevilacqua M, Chebat E, Bertora P, Cavaiani P, Baruto C, Fumagalli S, Raggi U. Metoclopramide increases vasopressin secretion. J Clin Endocrinol Metab 1986; 63:747-50.

43.       Bevilacqua M, Norbiato G, Chebat E, Raggi U, Cavaiani P, Guzzetti R, Bertora P. Osmotic and nonosmotic control of vasopressin release in the elderly: effect of metoclopramide. J Clin Endocrinol Metab 1987; 65:1243-7.

44.       Norbiato G, Bevilacqua M, Carella F, Chebat E, Raggi U, Bertora P, Grassi MP, Mangoni A. Alterations in vasopressin regulation in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1988; 51:903-8.

45.       Steardo L, Iovino M, Monteleone P, Bevilacqua M, Norbiato G. Evidence that cholinergic receptors of muscarinic type may modulate vasopressin release induced by metoclopramide. J Neural Transm Gen Sect 1990; 82:213-7.

46.       Norbiato G, Bevilacqua M, Righini V, Chebat E, Vago T, Bertora P, Castelli L, Mangoni A. Altered vasopressin response to metoclopramide in multiple system atrophy: evidence of a cholinergic defect in the hypothalamus. Acta Neurol Scand 1992; 85:299-303.

47.       Frisinghelli A, Crema C, Bevilacqua M, Chebat E, Turiel M. [Hemodynamic response to somatostatin at rest and during sympathetic activation in idiopathic orthostatic hypotension]. Cardiologia 1991; 36:199-206.

48.       Furlan R, Piazza S, Grittini A, Crema C, Chebat E, Bevilacqua M, Porta A, Baselli G, Lombardi F, Malliani A. Evidence for altered baroreceptive control of heart rate in pure autonomic failure. J Hypertens Suppl 1993; 11 Suppl 5:S174-5.

49.       Bevilacqua M, Norbiato G, Righini V, Vago T, Castelli L, Carella F, Caraceni T. Loss of osmotic thirst in multiple system atrophy: association with sinoaortic baroreceptor deafferentation. Am J Physiol 1994; 266:R1752-8.

50.       Furlan R, Piazza S, Bevilacqua M, Turiel M, Norbiato G, Lombardi F, Malliani A. Pure Autonomic Failure: complex abnormalities in the neural mechanisms regulating the cardiovascular system. J Auton Nerv Syst 1995; 51:223-35.

51.       Bevilacqua M, Norbiato G, Righini V, Castelli L, Rogolino A, Furlan R, Piazza S, Chebat E, Vago T. Atrial natriuretic peptide in multiple system atrophy. Am J Physiol 1996; 271:R1047-53.

52.       Lukezic M, Righini V, Di Natale B, De Angelis R, Norbiato G, Bevilacqua M, Chiumello G. Vasopressin and thirst in patients with posterior pituitary ectopia and hypopituitarism. Clin Endocrinol (Oxf) 2000; 53:77-83.

53.       Norbiato G, Bevilacqua M, Raggi U, Micossi P, Moroni C, Fasoli A. Effect of prostaglandin synthetase inhibitors on renin and aldosterone in man on a normal or low sodium diet. Acta Endocrinol (Copenh) 1978; 87:577-88.

54.       Norbiato G, Raggi U, Fasoli A, Bevilacqua M, Micossi P. Inhibition of prostaglandin synthesis and Bartter's syndrome. Lancet 1976; 2:1144.

55.       Norbiato G, Bevilacqua M, Meroni R, Raggi U, Dagani R, Scorza D, Frigeni G, Vago T. Effects of potassium supplementation on insulin binding and insulin action in human obesity: protein-modified fast and refeeding. Eur J Clin Invest 1984; 14:414-9.

56.       Bevilacqua M, Meroni R, Scorza D, Vago T, Norbiato G. [Effects of guanabenz on plasma renin and aldosterone and on sodium balance in hypertensive patients]. Minerva Cardioangiol 1984; 32:267-71.

57.       Bevilacqua M. [Recent findings on the importance of alpha 2 receptors at the central and peripheral levels]. Minerva Cardioangiol 1984; 32:247-52.

58.       Vago T, Bevilacqua M, Dagani R, Meroni R, Frigeni G, Santoliss C, Norbiato G. Comparison of rat and human left ventricle beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Biochem Biophys Res Commun 1984; 121:346-54.

59.       Vago T, Meroni R, Dagani R, Baldi G, Pagani M, Bevilacqua M, Norbiato G. Characterization of alpha 2-adrenoceptor binding properties of imidazoline-like drugs, azoloazepine derivatives and beta-phenethylamine-like drugs in human platelet membranes. J Pharm Pharmacol 1985; 37:593-6.

60.       Bevilacqua M, Norbiato G, Vago T, Meroni R, Dagani R, Raggi U, Frigeni G, Santoli C. Alterations in norepinephrine content and beta adrenoceptor regulation in myocardium bordering aneurysm in human heart: their possible role in the genesis of ventricular tachycardia. Eur J Clin Invest 1986; 16:163-8.

61.       Malacco E, Mailland F, Bosisio E, Meroni R, Dagani R, Renesto E, Bevilacqua M. Acute and long-term haemodynamic effects of propranolol and indenolol in hypertension. Eur J Clin Pharmacol 1986; 30:157-60.

62.       Bevilacqua M, Vago T, Norbiato G, Chebat E, Baldi G, Meroni R, Regalia E. Identification and characterization of alpha 1- and beta 2-adrenergic receptors in human liver. Eur J Clin Invest 1987; 17:330-5.

63.       Bevilacqua M, Savonitto S, Bosisio E, Chebat E, Bertora PL, Sardina M, Norbiato G. Role of the Frank-Starling mechanism in maintaining cardiac output during increasing levels of treadmill exercise in beta-blocked normal men. Am J Cardiol 1989; 63:853-7.

64.       Monopoli A, Forlani A, Bevilacqua M, Vago T, Norbiato G, Bertora P, Biglioli P, Alamanni F, Ongini E. Interaction of selected vasodilating beta-blockers with adrenergic receptors in human cardiovascular tissues. J Cardiovasc Pharmacol 1989; 14:114-20.

65.       Vago T, Bevilacqua M, Norbiato G, Baldi G, Chebat E, Bertora P, Baroldi G, Accinni R. Identification of alpha 1-adrenergic receptors on sarcolemma from normal subjects and patients with idiopathic dilated cardiomyopathy: characteristics and linkage to GTP-binding protein. Circ Res 1989; 64:474-81.

66.       Beretta L, Lemma M, Vanelli P, Botta M, Antonacci C, Bevilacqua M, Monopoli A, Santoli C. Gastroepiploic artery free graft for coronary bypass. Eur J Cardiothorac Surg 1990; 4:323-7; discussion 328.

67.       Bevilacqua M, Norbiato G, Chebat E, Baldi G, Bertora P, Regalia E, Colella G, Gennari L, Vago T. Changes in alpha-1 and beta-2 adrenoceptor density in human hepatocellular carcinoma. Cancer 1991; 67:2543-51.

68.       Vago T, Norbiato G, Baldi G, Chebat E, Bertora P, Bevilacqua M. Respiratory-burst stimulants desensitize beta-2 adrenoceptors on human polymorphonuclear leukocytes. Int J Tissue React 1990; 12:53-8.

69.       Bevilacqua M, Vago T, Monopoli A, Baldi G, Forlani A, Antona C, Biglioli P, Scrofani R, Norbiato G. Alpha 1 adrenoceptor subtype mediates noradrenaline induced contraction of the human internal mammary artery: radioligand and functional studies. Cardiovasc Res 1991; 25:290-4.

70.       Bevilacqua M, Vago T, Norbiato G. Effect of propionyl-L-carnitine on L-type calcium channels in human heart sarcolemma. Cardiovasc Drugs Ther 1991; 5 Suppl 1:31-5.

71.       Savonitto S, Bevilacqua M, Chebat E, Vago T, Bertora P, Baldi G, Renesto E, Peruzzi E, Sardina M, Norbiato G. Beta-adrenergic receptors and reflex tachycardia after single and repeated felodipine administration in essential hypertension. J Cardiovasc Pharmacol 1991; 17:970-5.

72.       Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106:2454-8.

73.       Dallegri F, Ottonello L, Dapino P, Bevilacqua M. The anti-inflammatory drug nimesulide rescues alpha-1-proteinase inhibitor from oxidative inactivation by phagocytosing neutrophils. Respiration 1992; 59:1-4.

74.       Barbareschi M, Vago T, Colombo D, Bevilacqua M. Terbinafine induces the PMNL priming effect and enhances in vitro PMNL fungicidal activity against Candida albicans blastospores. Mycoses 1993; 36:405-9.

75.       Bevilacqua M, Magni E. Recent contributions to knowledge of the mechanism of action of nimesulide. Drugs 1993; 46 Suppl 1:40-7.

76.       Bevilacqua M, Vago T, Baldi G, Renesto E, Dallegri F, Norbiato G. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacol 1994; 268:415-23.

77.       Vago T, Baldi G, Colombo D, Barbareschi M, Norbiato G, Dallegri F, Bevilacqua M. Effects of naftifine and terbinafine, two allylamine antifungal drugs, on selected functions of human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1994; 38:2605-11.

78.       Dallegri F, Ottonello L, Bevilacqua M. Possible modes of action of nimesulide in controlling neutrophilic inflammation. Arzneimittelforschung 1995; 45:1114-7.

79.       Ottonello L, Dapino P, Scirocco MC, Balbi A, Bevilacqua M, Dallegri F. Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation? Clin Sci (Lond) 1995; 88:331-6.

80.       Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneimittelforschung 1995; 45:1096-8.

81.       Vago T, Bevilacqua M, Conci F, Rogolino A, Norbiato G. Pharmacologic data reveal the heterogeneity of angiotensin-converting enzyme according to its source (lung versus heart). Am J Cardiol 1995; 75:13F-17F.

82.       Bevilacqua M, Vago T, Rogolino A, Conci F, Santoli E, Norbiato G. Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries, and veins. J Cardiovasc Pharmacol 1996; 28:494-9.

83.       Bettica P, Masino M, Cucinotta E, Vago T, Norbiato G, Moro L, Suarez KN, Romanello M, Bevilacqua M. Comparison of the clinical performance of the immunoenzymometric assays for N-terminal and C-terminal type I collagen telopeptides and the HPLC assay for pyridinium cross-links. Eur J Clin Chem Clin Biochem 1997; 35:63-8.

84.       Bevilacqua M, Vago T, Baldi G, Norbiato G, Masson S, Latini R. Analytical agreement and clinical correlates of plasma brain natriuretic peptide measured by three immunoassays in patients with heart failure. Clin Chem 1997; 43:2439-40.

85.       Masson S, Latini R, Bevilacqua M, Vago T, Sessa F, Torri M, Anesini A, Salio M, Pasotti E, Agnello D, Santoro L, Catania A, Ghezzi P, Moccetti T, Maggioni AP. Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res 1998; 37:213-7.

86.       Masson S, Vago T, Baldi G, Salio M, De Angelis N, Nicolis E, Maggioni AP, Latini R, Norbiato G, Bevilacqua M. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med 2002; 40:761-3.